Can a Low-Dose immune calmer slow Alzheimer's decline?

NCT ID NCT05468073

Ongoing Disease control Sponsor: Centre Hospitalier St Anne Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether low-dose interleukin-2 (IL-2), an immune-modulating drug, can slow cognitive decline in people with early Alzheimer's disease. Forty participants will receive either IL-2 injections or a placebo for several months, and their cognitive function will be tracked over 18 months. The goal is to see if calming certain immune cells can protect the brain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-dose interleukin-2 (IL-2), given as subcutaneous injections
What this could lead to: If it works, this could point toward a new way to slow memory loss and functional decline in early Alzheimer's by calming the immune system.
What could go wrong: This is a small, early-phase trial. The immune approach is experimental, and it is unknown whether it will meaningfully slow cognitive decline or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Neuroinflammatory Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Show contact details

Locations

GHU Saint Anne

Paris, 75674, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.